ASH 2020 | Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML
Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, presents the safety and clinical activity data from a Phase I study (NCT02890329) of decitabine (DAC) plus ipilimumab (IPI) in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in the post bone marrow transplant (BMT) or treatment naïve setting. IPI targets CTLA-4, blocking its immune inhibition and thus enhancing T cell-mediated malignant cell cytotoxicity. The addition of DAC was intended to increase this action and the results from the study showed encouraging response rates in both arms. Immune-related adverse events were frequent in both arms but similar to prior data. The activity of the combination therapy, specifically for transplant-naïve individuals, indicates that an alloreactive environment is not necessary for CTLA-4 blockade success with IPI. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Jacqueline Garcia, MD, has received institutional/trial support from Eli Lily, Pfizer, Genentech and AbbVie, and is on the scientific advisory board for AbbVie.
